Misplaced Pages

Abarelix

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Plenaxis) Chemical compound Pharmaceutical compound
Abarelix
Clinical data
Trade namesPlenaxis
AHFS/Drugs.comMonograph
Routes of
administration		Intramuscular injection
Drug classGnRH analogue; GnRH antagonist; Antigonadotropin
ATC code
Pharmacokinetic data
Protein binding96–99%
Identifiers
IUPAC name
  • N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparagyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC72H95ClN14O14
Molar mass1416.09 g·mol
3D model (JSmol)
SMILES
  • CC(C)C(NC(=O)(CC(N)=O)NC(=O)(Cc1ccc(O)cc1)N(C)C(=O)(CO)NC(=O)(Cc2cccnc2)NC(=O)(Cc3ccc(Cl)cc3)NC(=O)(NCc5ccc4ccccc4c5)NC(C)=O)C(=O)N(CCCCNC(C)C)C(=O)N6CCC6C(=O)N(C)C(N)=O
InChI
  • InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1
  • Key:AIWRTTMUVOZGPW-HSPKUQOVSA-N
  (what is this?)  (verify)

Abarelix, sold under the brand name Plenaxis, is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist) which is marketed in Germany and the Netherlands. It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.

It was originally marketed by Praecis Pharmaceuticals as Plenaxis, and is now marketed by Speciality European Pharma in Germany after receiving a marketing authorization in 2005. The drug was introduced in the United States in 2003, but was discontinued in this country in May 2005 due to poor sales and a higher-than-expected incidence of severe allergic reactions. It remains marketed in Germany and the Netherlands however.

See also

References

  1. "Abarelix". PubChem. 2017-07-29.
  2. ^ "Abarelix". Drugs.com. Archived from the original on 2018-02-10. Retrieved 2018-01-23.
  3. Boccon-Gibod L, van der Meulen E, Persson BE (June 2011). "An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer". Therapeutic Advances in Urology. 3 (3): 127–40. doi:10.1177/1756287211414457. PMC 3159401. PMID 21904569.
  4. Pharmazeutische Zeitung online: Abarelix (in German)
  5. Minev B (13 January 2011). Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Springer Science & Business Media. pp. 182–. ISBN 978-90-481-9704-0.
  6. "Abarelix". Drugs.com. Archived from the original on 2019-08-29. Retrieved 2018-08-27.
GnRHTooltip Gonadotropin-releasing hormone and gonadotropins
GnRH modulators
(incl. analogues)
Agonists
Antagonists
Gonadotropins
Preparations
Others
(indirect)
Progonadotropins
Antigonadotropins
See also
GnRH and gonadotropin receptor modulators
Androgens and antiandrogens
Estrogens and antiestrogens
Progestogens and antiprogestogens
GnRHTooltip Gonadotropin-releasing hormone receptor and gonadotropin receptor modulators
GnRHTooltip Gonadotropin-releasing hormone receptor
Gonadotropin
LH/hCGTooltip Luteinizing hormone/choriogonadotropin receptor
FSHTooltip Follicle-stimulating hormone receptor


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: